Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells

BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide. The only drug currently approved for clinical use in the treatment of advanced HCC is sorafenib. However, many patients with HCC show reduced sensitivity to sorafenib during treatment. SIRT3, a member...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Jo, Hanhee, Park, Yusun, Kim, Taehun, Kim, Jisu, Lee, Jong Sook, Kim, Seon Yoo, Chung, Jee-in, Ko, Hae yong, Pyun, Jae-Chul, Kim, Kyung Sik, Lee, Misu, Yun, Mijin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7168998/
https://ncbi.nlm.nih.gov/pubmed/32306906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06822-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados